NCT07622654 Effect of Emotion-Focused Acceptance and Commitment Therapy on Obsessive-Compulsive Disorder Symptom Severity
| NCT ID | NCT07622654 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mehmet Emrah Karadere |
| Condition | OCD |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 36 participants in total. It began in 2025-10-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate the effect of Emotion-Focused Acceptance and Commitment Therapy (ACT) group psychotherapy on obsessive-compulsive disorder (OCD) symptom severity. Participants with OCD will be randomly assigned to either an ACT-based group psychotherapy arm or a supportive group psychotherapy arm. Each arm consists of 10 to 12 weekly sessions of 2 hours. Symptom severity, psychological flexibility, emotional awareness, functioning and quality of life will be assessed before and after the intervention.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Obsessive-Compulsive Disorder according to DSM-5 criteria * Age between 18-65 years * Minimum literacy level * Willingness to participate and providing informed consent Exclusion Criteria: * Age over 65 years * Diagnosis of alcohol or substance use disorder * Comorbid psychotic disorder or intellectual disability * Any change in psychiatric treatment (medication or psychotherapy) in the last 3 months * Comorbid psychiatric disorder that would impair group therapy compliance * History of cognitive impairment due to dementia, organic brain syndrome or other neurological/organic pathology
Contact & Investigator
Mehmet Emrah Karadere
PRINCIPAL INVESTIGATOR
Goztepe Prof Dr Suleyman Yalcın City Hospital
Frequently Asked Questions
Who can join the NCT07622654 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying OCD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07622654 currently recruiting?
Yes, NCT07622654 is actively recruiting participants. Contact the research team at memrahkaradere@gmail.com for enrollment information.
Where is the NCT07622654 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07622654 clinical trial?
NCT07622654 is sponsored by Mehmet Emrah Karadere. The principal investigator is Mehmet Emrah Karadere at Goztepe Prof Dr Suleyman Yalcın City Hospital. The trial plans to enroll 36 participants.